# US 2019/0317106 A1 · Kidney disease prognosis prediction method and system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317106 A1
- Document ID: US20190317106A1
- Status: Published application
- Kind: A1
- Application number: 16/302,226
- Filed: 2017-05-17
- Published: 2019-10-17
- Earliest claimed: 2016-05-17
- Assignees: Osaka University; Shiseido Company, Ltd.
- Applicants: Osaka University
- Inventors: Yoshitaka Isaka; Tomonori Kimura; Keiko Yasuda; Kenji Hamase; Masashi Mita
- Web page: https://patentgrep.com/patent/US20190317106A1

## CPC

- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6812: {Assays for specific amino acids}
- G01N 33/72: involving blood pigments, e.g. haemoglobin, bilirubin {or other porphyrins; involving occult blood}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16B 40/20: Supervised data analysis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The purpose of the present invention is to provide: a method for predicting the prognosis for kidney disease for a subject on the basis of the amount of D- and L-amino acids, from a blood sample; and an analysis system that determines prognosis predictions. This purpose is achieved by using at least one amino acid to predict the prognosis for kidney disease, said amino acid being selected from the group consisting of D-serine, D-asparagine, D-proline, D-alanine, D-leucine, D-lysine, D-allo-isoleucine, L-glutamic acid, L-alanine, L-tryptophan, and L-asparagine.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A method for predicting a prognosis for kidney outcome which is death or renal replacement therapy in a subject who has not been subjected to a dialysis, comprising:
a step for measuring the amount of at least one D-amino acid selected from the group consisting of D-serine, D-asparagine, D-proline, D-alanine, D-leucine, D-lysine, D-allo-isoleucine in a blood sample of the subject, and
a step for correlating an index value based on the amount of amino acid with a prognosis for the subject
a step for carrying out treatment selected from the group consisting of lifestyle improvement, dietary counseling, blood pressure management, blood sugar management and lipid management.

### Claim 14 (depends on 13)

The prognosis prediction method according to claim 13, wherein prognosis is determined according to a predetermined cutoff value for the index value in the correlation step.

### Claim 15 (depends on 14)

The prognosis prediction method according to claim 14, wherein the cutoff value is predetermined by a Kaplan-Meier curve analysis.

### Claim 16 (depends on 15)

The prognosis prediction method according to claim 15, wherein the cutoff value is 5.6 μmol/L for D-serine, 0.7 μmol/L for D-asparagine, 4.7 μmol/L for D-proline, 5.2 μmol/L for D-alanine, 0.5 μmol/L for D-leucine, 0.6 μmol/L for D-lysine, 0.1 μmol/L for D-alloisoleucine.

### Claim 17 (depends on 13)

The prognosis prediction method according to claim 13, further comprising a step for measuring the amount of an isomer corresponding to the amino acid, wherein the index value is the ratio of the amount of the amino acid to the amount of the corresponding isomer.

### Claim 18 (depends on 13)

The prognosis prediction method according to claim 13, wherein the index value is further adjusted for one or more variables selected from the group consisting of eGFR, urinary protein level, diabetes, age, gender, hemoglobin level, mean blood pressure, history of cardiovascular events and presence or absence of anti-hypertensive drug treatment.

### Claim 19 (depends on 13)

The prognosis prediction method according to claim 13, wherein the treatment is blood pressure management comprising administration of an ACE inhibitor or ARB.

### Claim 20 (depends on 13)

The prognosis prediction method according to claim 13, wherein the treatment is blood sugar management comprising administration of insulin.

### Claim 21 (depends on 13)

The prognosis prediction method according to claim 13, wherein the treatment is lipid management comprising administration of hyperlipidemia drugs.

### Claim 22

A prognosis prediction analysis system for kidney outcome which consists of death and renal replacement therapy, comprising a storage unit, an input unit, a data processing unit comprising a CPU, and an output unit, and the CPU executing the following step:
inputting cutoff values of index values based on the amounts of chiral amino acids in the blood and prognosis information for determining a prognosis for kidney disease from the input unit and storing in the storage unit,
inputting measured amounts of chiral amino acids in the blood of a subject who has not been subjected to a dialysis from the input unit and storing in the storage unit,
calculating index values based on the measured amounts of chiral amino acids stored in the storage unit by the data processing unit and comparing with the cutoff values stored with the index values to determine prognosis information for said subject, and
outputting prognosis information to the output unit; wherein,
the chiral amino acids in the blood are at least one amino acid selected from the group consisting of D-serine, D-asparagine, D-proline, D-alanine, D-leucine, D-lysine, D-alloisoleucine, L-glutamic acid, L-alanine, L-tryptophan, L-asparagine and L-aspartic acid.

### Claim 23 (depends on 22)

The prognosis prediction analysis system according to claim 22, further containing an analysis/measurement unit, wherein the analysis/measurement unit separates chiral amino acids in the blood from a blood sample of a subject and assays the amounts thereof to determine the measured amounts thereof, and inputs the measured amounts instead of the input unit or via the input unit.

### Claim 24 (depends on 23)

The prognosis prediction analysis system according to claim 23, wherein the analysis/measurement unit comprising optical resolution column system.

### Claim 25 (depends on 22)

The prognosis prediction analysis system according to claim 22, wherein the cutoff value is predetermined by a Kaplan-Meier curve analysis.

### Claim 26 (depends on 25)

The prognosis prediction analysis system according to claim 25, wherein the cutoff value is 5.6 μmol/L for D-serine, 0.7 μmol/L for D-asparagine, 4.7 μmol/L for D-proline, 5.2 μmol/L for D-alanine, 0.5 μmol/L for D-leucine, 0.6 μmol/L for D-lysine, 0.1 μmol/L for D-alloisoleucine,

### Claim 27 (depends on 22)

The prognosis prediction analysis system according to claim 22, wherein the measured amount of an isomer corresponding to the amino acid is further input from the input unit, and the index value is the ratio of the amount of the amino acid to the amount of the corresponding isomer.

### Claim 28 (depends on 22)

The prognosis prediction analysis system according to claim 22, wherein the index value is further adjusted for one or more variables selected from the group consisting of eGFR, urinary protein level, diabetes, age, gender, hemoglobin level, mean blood pressure, history of cardiovascular events and presence or absence of anti-hypertensive drug treatment.
